Introduction Free light chains (FLCs) are a well-established biomarker of plasma cell dyscrasias. FLCs exist as monomers, dimers and oligomers. Lambda FLC is particularly prone to form dimers and oligomers. Under certain pathological conditions, such as in AL amyloidosis and multiple myeloma (MM), high levels of FLC dimers can be found even [...]
Introduction Bone marrow (BM)-based minimal residual disease (MRD) has been established as one of the most important dynamic prognostic markers in multiple myeloma (MM). However, the necessity of bone marrow biopsies limits the feasibility of frequent MRD monitoring. Consequently, there is an urgent unmet need for peripheral blood-based MRD testing for serial [...]
Introduction The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma. However, MRD tests in current clinical use require bone marrow (BM) samples that are uncomfortable, expensive, and time-consuming for patients. BM-based assays are also limited by sampling of a single location within the marrow, which may [...]